Feb 20, 2020 • 4:15pm EST

Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results

-- Received FDA Guidance Following Type-C Meeting to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic HCT Recipients; Enrollment Expected in Q2 2020 -- -- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010 for the Treatment of IBS-C -- Conference Call Today at 4:30 p.m. (ET) -- ROCKVILLE, Md., Feb. 20, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent an...